|
Aug 11
|
Why Eli Lilly (LLY) Stock Is Trading Up Today
|
|
Aug 11
|
Lilly first to opt for confidential reimbursement price in Germany
|
|
Aug 11
|
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
|
|
Aug 11
|
Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron
|
|
Aug 11
|
Lilly (LLY) Reliance on International Sales: What Investors Need to Know
|
|
Aug 11
|
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?
|
|
Aug 11
|
Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform
|
|
Aug 9
|
Eli Lilly (LLY) Partners With Senderra For Innovative Digital Patient Care Solution
|
|
Aug 9
|
Apple notches best week in years; Trump shakes Fed leadership: This Week in markets
|
|
Aug 8
|
Why Novo Nordisk Stock Flew Higher on Friday
|
|
Aug 8
|
Why Eli Lilly Stock Sank 18% This Week
|
|
Aug 8
|
GLP-1 race heats up: Where Eli Lilly stands after weak trial data
|
|
Aug 8
|
Health Care Roundup: Market Talk
|
|
Aug 8
|
Investing.com’s stocks of the week
|
|
Aug 8
|
Eli Lilly (LLY) Sees Revenue Surge With Innovative Treatments And Raised Earnings Guidance
|
|
Aug 8
|
This Unusually Active Wayfair Put Option Explains a Lot About the Current Markets
|
|
Aug 8
|
Did Eli Lilly Stock Just Have Its Novo Nordisk Moment?
|
|
Aug 8
|
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
|
|
Aug 8
|
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
|
|
Aug 8
|
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
|